Amod A. Sarnaik
Amod Sarnaik led the pivotal lifileucel trial that produced the first approved TIL therapy.
Surgical oncologist and principal investigator of C-144-01, the study that led to lifileucel's 2024 accelerated approval in advanced melanoma.
| Title | Journal | Year |
|---|---|---|
| Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma | Journal of Clinical Oncology | 2021 |
Pages like this
not linked directly; found by shared links- CompanyIovance Biotherapeutics
Shares C-144-01, C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed, Lifileucel, TIL therapy.
- PersonShari Pilon-Thomas
Shares Moffitt Cancer Center, TIL therapy, Melanoma.
- PairingPD-1 failure → TIL therapy
Shares Lifileucel, TIL therapy, Melanoma.
- PersonSteven A. Rosenberg
Shares C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed, Lifileucel, TIL therapy, Melanoma.
- PersonPatrick Hwu
Shares Moffitt Cancer Center, TIL therapy, Melanoma.
- Key paperRohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma
Shares C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed, Lifileucel, TIL therapy, Melanoma.
- ProductAldesleukin (high-dose IL-2)
Shares C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed, TIL therapy, Melanoma.
- PersonPamela S. Ohashi
Shares TIL therapy, Melanoma.